user fee
A fee drug companies pay the FDA per drug review under PDUFA; the funds are dedicated largely to speeding up drug approvals.
As defined in Marcia Angell on Big Pharma
Where it comes up · 3
- Marcia Angell on Big Pharma1 claim
- Vanessa Williamson on Taxes and Read My Lips1 claim
- Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant1 claim
Most important claims · 3 of 3Search all claims for “user fee” →
- The gas tax illustrates why hiding taxes is bad: people dislike it despite liking the roads it funds, because they cannot see how much it is, it varies for reasons that make no sense to them, and being volume-based rather than price-based it behaves counterintuitively—so it has all the downsides of invisibility and none of the appeal of a visible user-fee-style tax.Vanessa Williamson on Taxes and Read My Lips
- Because drug companies pay per-drug 'user fees' that now fund over half the budget of the FDA's drug-approval division and can only be used to speed approvals, the FDA has a financial incentive to approve as many drugs as fast as possible, which explains why US approval is now the fastest in the world.Marcia Angell on Big Pharma
- Instead of the conflicted company designing, conducting, and reporting its own registration trial, the company should pay a much larger fee (e.g. $32-52 million instead of $2 million) and supply the drug, while the FDA or an impartial third party designs the control arm, population, post-protocol therapy, and statistical plan and runs the trial; once the Data and Safety Monitoring Board declares success, the drug is approved instantly with no back-end review, which removes the conflict, prevents gaming, and could even save a year of regulatory time.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant